Story perspectives

Genomic Test May Spare Chemo; Hormone Therapy Holds; Darolutamide Safer

5/30/2026

Summary

Story summary

A genomic test that evaluates 50 tumor genes may let millions of women skip chemotherapy.
The Optima trial of 4,429 hormone-positive breast-cancer patients across six countries showed five-year cancer-free survival of 94.9% with chemotherapy plus hormone therapy and 93.7% with hormone therapy alone, indicating non-inferior outcomes for the low-score group.
In a 24-week study, darolutamide (Nubeqa) produced a 15.8% median cognitive decline versus 36.1% for enzalutamide (Xtandi).

1 of 1

Story summary

A genomic test that evaluates 50 tumor genes may let millions of women skip chemotherapy.
The Optima trial of 4,429 hormone-positive breast-cancer patients across six countries showed five-year cancer-free survival of 94.9% with chemotherapy plus hormone therapy and 93.7% with hormone therapy alone, indicating non-inferior outcomes for the low-score group.
In a 24-week study, darolutamide (Nubeqa) produced a 15.8% median cognitive decline versus 36.1% for enzalutamide (Xtandi).